You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-c-Maf antibody (ab55502)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-c-Maf antibody
See all c-Maf products (6) ...

Description

Mouse monoclonal to c-Maf

Tested applications

WBmore details

Cross reactivity

Reacts with

Recombinant Fragment

Predicted to work with

Human

Immunogen

Recombinant fragment: SCRFKRVQQR HVLESEKNQL LQQVDHLKQE ISRLVRERDA YKEKYEKLVS SGFRENGSSS DNPSSPEFFI TEPTRKLEPS VGYATFWKPQ HRVLTSVFTK , corresponding to amino acids 304-404 of Human c-Maf

SCRFKRVQQR HVLESEKNQL LQQVDHLKQE ISRLVRERDA YKEKYEKLVS SGFRENGSSS DNPSSPEFFI TEPTRKLEPS VGYATFWKPQ HRVLTSVFTK

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: None
PBS, pH 7.2

Concentration

Concentration information loading...

Purity

Protein G purified

Clonality

Monoclonal

Isotype

IgG2b

Light chain type

kappa

  • Western blot - c-Maf antibody (ab55502)Western blot - c-Maf  antibody (ab55502) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab55502 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application notes

WB: Use at a concentration of 1-5 µg/ml.

This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Target

Function

Acts as a transcriptional activator or repressor. Involved in embryonic lens fiber cell development. Recruits the transcriptional coactivators CREBBP and/or EP300 to crystallin promoters leading to up-regulation of crystallin gene during lens fiber cell differentiation. Activates the expression of IL4 in T helper 2 (Th2) cells. Increases T cell susceptibility to apoptosis by interacting with MYB and decreasing BCL2 expression. Together with PAX6, transactivates strongly the glucagon gene promoter through the G1 element. Activates transcription of the CD13 proximal promoter in endothelial cells. Represses transcription of the CD13 promoter in early stages of myelopoiesis by affecting the ETS1 and MYB cooperative interaction. Involved in the initial chondrocyte terminal differentiation and the disappearance of hypertrophic chondrocytes during endochondral bone development. Binds to the sequence 5'-[GT]G[GC]N[GT]NCTCAGNN-3' in the L7 promoter. Binds to the T-MARE (Maf response element) sites of lens-specific alpha- and beta-crystallin gene promoters. Binds element G1 on the glucagon promoter. Binds an AT-rich region adjacent to the TGC motif (atypical Maf response element) in the CD13 proximal promoter in endothelial cells (By similarity). When overexpressed, represses anti-oxidant reponse element (ARE)-mediated transcription. Involved either as an oncogene or as a tumor suppressor, depending on the cell context. Binds to the ARE sites of detoxifying enzyme gene promoters.

Tissue specificity

Expressed in endothelial cells.

Involvement in disease

Note=A chromosomal aberration involving MAF is found in some forms of multiple myeloma (MM). Translocation t(14;16)(q32.3;q23) with an IgH locus.
Defects in MAF are the cause of cataract pulverulent juvenile-onset MAF-related (CAPJOM) [MIM:610202]. A form of cataract with nuclear or cortical pulverulent opacities. Pulverulent cataracts are characterized by a dust-like, 'pulverised' appearance of the opacities which can be found in any part of the lens. The phenotype shows significant intra- and interfamilial variation, both in the distribution of the cataract and the degree of opacification. Some patients with cataract pulverulent juvenile-onset can present microcornea and bilateral iris colobomas in addition to cataract.
Defects in MAF are the cause of cataract congenital cerulean type 4 (CCA4) [MIM:610202]. A cerulean form of congenital cataract. Cerulean cataracts are characterized by peripheral bluish and white opacifications organized in concentric layers with occasional central lesions arranged radially. The opacities are observed in the superficial layers of the fetal nucleus as well as the adult nucleus of the lens. Involvement is usually bilateral. Visual acuity is only mildly reduced in childhood. In adulthood, the opacifications may progress, making lens extraction necessary. Histologically the lesions are described as fusiform cavities between lens fibers which contain a deeply staining granular material. Although the lesions may take on various colors, a dull blue is the most common appearance and is responsible for the designation cerulean cataract.

Sequence similarities

Belongs to the bZIP family. Maf subfamily.
Contains 1 bZIP domain.

Post-translational
modifications

Ubiquitinated, leading to its degradation by the proteasome. Ubiquitination is triggered by glucocorticoids.
Phosphorylated by GSK3 and MAPK13 on serine and threonine residues (Probable). The phosphorylation status can serve to either stimulate or inhibit transcription.

Cellular localization

Nucleus.

Target information above from: UniProt accessionO75444 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • AS42 oncogene homolog antibody
  • Avian musculoaponeurotic fibrosarcoma (MAF) protooncogene antibody
  • Avian musculoaponeurotic fibrosarcoma (v maf) antibody
  • c maf proto oncogene antibody
  • cMaf antibody
  • maf antibody
  • MAF_HUMAN antibody
  • MAF2 antibody
  • MGC71685 antibody
  • Proto oncogene c Maf antibody
  • Proto-oncogene c-maf antibody
  • Transcription factor Maf antibody
  • v maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) antibody
  • v maf musculoaponeurotic fibrosarcoma oncogene homolog antibody
  • V-maf musculoaponeurotic fibrosarcoma oncogene homolog antibody
see all

Anti-c-Maf antibody images:

  Western blot - c-Maf antibody (ab55502)

Western blot - c-Maf  antibody (ab55502)

Western blot against tagged recombinant protein immunogen using ab55502 c-Maf antibody at 1ug/ml. Predicted band size of immunogen is 37 kDa.

This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

References for Anti-c-Maf antibody (ab55502)

ab55502 has not yet been referenced specifically in any publications.

Publishing research using ab55502? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"